3-[4-(4,5-dihydro-1H-imidazol-2-ylamino)phenyl]-1-(phenyl)propan-1-one | 427896-85-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: 3-[4-(4,5-dihydro-1H-imidazol-2-ylamino)phenyl]-1-(phenyl)propan-1-one
• 英文别名: 3-[4-(4,5-dihydro-1H-imidazol-2-ylamino)phenyl]-1-phenylpropan-1-one
• CAS: 427896-85-3
• 化学式: C₁₈H₁₉N₃O
• 分子量: 293.368
• InChiKey: DXEGFCISSXHHNK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  53.5
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• SUBSTITUTED 2-PHENYLAMINOIMIDAZOLINE PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1339694A1

  公开（公告）日：2003-09-03
• US6417186B1
  申请人：——

  公开号：US6417186B1

  公开（公告）日：2002-07-09
• [EN] SUBSTITUTED 2-PHENYLAMINOIMIDAZOLINE PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS<br/>[FR] DERIVES DE 2-PHENYLAMINOIMIDAZOLINE PHENYLE CETONE SUBSTITUES UTILISES COMME ANTAGONISTES DE LA PROSTAGLANDINE I2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2002040453A1

  公开（公告）日：2002-05-23

  This invention relates to compounds which are generally prostaglandins I2 (IP) receptor modulators, particularly IP receptor antagonists, and which are represented by the general formula (I) wherein A, R?1 and R2¿ are defined in the specification; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, a process for the preparation of such compounds and their use for treating diseases associated with pain, inflammation, urinary tract disease states, respiratory disease states, edema formation, or hypotensive vascular diseases.